TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03876509

Intervention type: DIAGNOSTIC_TEST
Intervention: Impedance Cardiography
Description: Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured.
Study: NCT03285581

Intervention type: DEVICE
Group type: OTHER
Intervention: truSculpt RF
Description: Subjects will receive RF treatments
Study: NCT03990168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: 1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fluency intervention/ Delayed Auditory Feedback
Description: Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: fluency intervention/ Delayed Auditory Feedback
Description: Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
Study: NCT02539160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
Study: NCT00386152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Description: 80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Description: 80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: 500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
Study: NCT04881669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: obturator
Description: variable bulbs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: obturator
Description: variable bulbs
Study: NCT02861924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microcirculatory responses
Description: The effect of the duration and intensity of the pressure; reproducibility and correlation with ischemic hyperemia post.~measurements are made with the Imager SPECKLE imager (LSCI) give the microvascular perfusion data in arbitrary units called perfusion units (UP).
Study: NCT03270969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate/Emtricitabine
Description: Participants will receive daily TDF/FTC for 14 days
Study: NCT04881669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: obturator
Description: variable bulbs
Study: NCT02512120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: volume controlled ventilation
Description: After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: autoflow-volume controlled ventilation
Description: After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used.
Study: NCT02183948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01417949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time of starting antiretroviral therapy
Description: Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time of starting antiretroviral therapy
Description: Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit.
Study: NCT01112059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg twice a day for 8 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02251899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease-Management intervention
Description: The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
Study: NCT01525017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combig-DC (allogeneic dendritic cells) Cancer Vaccine
Description: Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
Study: NCT02953119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Study: NCT02134990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D and Oshadi R
Description: Anti cancer agents
Study: NCT03975881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application on smartphone
Description: The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
Study: NCT03350763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tannenbaum 10 Fr biliary stent
Description: Tannenbaum 10 Fr biliary stent
Study: NCT02134990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotheraphy
Study: NCT01946932

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temperature treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temperature treatment
Study: NCT01995513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: 1000 mg by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Enzalutamide
Description: Sugar pill manufactured to mimic Enzalutamide 40 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg by mouth twice daily
Study: NCT03893084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnancy preparation training
Description: Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
Study: NCT01662687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso patch
Description: Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril inj.+Kytril tab.
Description: Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4.
Study: NCT00200902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)
Description: Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal Clinical Interaction (ICI)
Description: Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
Study: NCT00611624

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mammosite brachytherapy radiation
Description: Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
Study: NCT01403051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Description: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Description: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for calcium carbonate
Description: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for vitamin D3
Description: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Study: NCT02295501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTERCEPT Plasma
Description: Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
Study: NCT03350763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expandable metallic biliary stent
Description: ie WallFlex biliary RX
Study: NCT03166774

Intervention type: OTHER
Intervention: Program of support of the sexual health
Description: Patients included in the study have to answer to a questionnaire
Study: NCT05096910

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Closure with monofilament or polyfilament suture materials
Description: Postoperative 6th-month isthmocele rates

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Closure with monofilament or polyfilament suture materials
Description: Postoperative 6th-month isthmocele rates
Study: NCT02574598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-3475
Description: The dosing interval of pembrolizumab can be increased in case of toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: The dosing interval of pembrolizumab can be increased in case of toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Use on both arms as standard of care.
Study: NCT02062385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V260
Description: V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
Study: NCT02733536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC
Description: C-MAC introduced with a h size 3 blade.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC
Description: C-MAC introduced with a h size 3 blade.
Study: NCT01424345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjustment of immunosuppressant dosages
Description: adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjustment of the dosages of immunosuppressants
Description: adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
Study: NCT02516202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vagifem
Description: One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Replens
Description: 2.5 gm to be applied vaginally every 3 days over 12 weeks.
Study: NCT02062385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V260
Description: V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to V260
Description: Placebo control

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to V260
Description: Placebo control

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OPV
Description: Oral poliovirus vaccine administered according to the standard of care

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OPV
Description: Oral poliovirus vaccine administered according to the standard of care
Study: NCT01119092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grade IV AP joint mobilizations
Description: 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
Study: NCT01065701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
Study: NCT02062385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPV
Description: Oral poliovirus vaccine administered according to the standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPV
Description: Oral poliovirus vaccine administered according to the standard of care

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DTaP
Description: Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
Study: NCT03138161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
Study: NCT02062385

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DTaP
Description: Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
Study: NCT01499966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaster of Paris/ Tubigrip
Description: After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks
Study: NCT02062385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP
Description: Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP
Description: Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
Study: NCT02516202

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Dispensed in visually identical bottle and tablet form to Vagifem.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Dispensed in visually identical bottle and tablet form to Vagifem.
Study: NCT02574598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Use on both arms as standard of care.
Study: NCT03489460

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Specialized sleep-related message interventions
Description: Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Specialized sleep-related message interventions
Description: Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.